









市场行情
/
股票
/
nasdaq-agen
/

Agenus Inc

AGEN

3.395USD

-0.045-1.31%

交易中（美东）报价延迟15分钟

111.40M总市值

亏损市盈率 TTM



Agenus Inc

3.395

-0.045-1.31%

概览公司财务分析

概览

公司

财务

分析

关于 Agenus Inc 公司

Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Agenus Inc简介



公司代码AGEN

公司名称Agenus Inc

上市日期Feb 04, 2000

CEOArmen (Garo H)

员工数量316

证券类型Ordinary Share

年结日Feb 04

公司地址3 Forbes Rd

城市LEXINGTON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02421-7305

电话17816744400

网址https://agenusbio.com/

公司代码AGEN

上市日期Feb 04, 2000

CEOArmen (Garo H)

Agenus Inc公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Christine M. Klaskin

Vice President - Finance

23.48K

+205.07%

Mr. Thomas L. (Tom) Harrison, Ph.D.

Independent Director

22.08K

+35.46%

Mr. Brian J. Corvese

Independent Director

4.60K

Wright (Timothy R)

Lead Independent Director

2.77K

Dr. Garo H. Armen, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

Mr. Richard Goldberg

Chief Development Officer

Dr. Steven O'Day, M.D.

Chief Medical Officer

Dr. Jennifer S. Buell, Ph.D.

Director

Ms. Susan F. Hirsch

Independent Director

名称

名称/职务

职务

持股

持股变动

Ms. Christine M. Klaskin

Vice President - Finance

23.48K

+205.07%

Mr. Thomas L. (Tom) Harrison, Ph.D.

Independent Director

22.08K

+35.46%

Mr. Brian J. Corvese

Independent Director

4.60K

Wright (Timothy R)

Lead Independent Director

2.77K

Dr. Garo H. Armen, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

Mr. Richard Goldberg

Chief Development Officer

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

Non-cash royalty revenue

24.83M

96.65%

Other services

526.00K

2.05%

Clinical product revenue

334.00K

1.30%

地区USD

名称

营收

占比

United States

25.16M

97.95%

Rest of World

526.00K

2.05%

业务

地区

业务USD

名称

营收

占比

Non-cash royalty revenue

24.83M

96.65%

Other services

526.00K

2.05%

Clinical product revenue

334.00K

1.30%

股东统计

更新时间: 12月20日周六

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

7.56%

Invus Public Equities Advisors, LLC

3.13%

B. Riley Financial, Inc

2.23%

Morgan Stanley & Co. LLC

1.45%

BlackRock Institutional Trust Company, N.A.

1.38%

其他

84.26%

持股股东

占比

The Vanguard Group, Inc.

7.56%

Invus Public Equities Advisors, LLC

3.13%

B. Riley Financial, Inc

2.23%

Morgan Stanley & Co. LLC

1.45%

BlackRock Institutional Trust Company, N.A.

1.38%

其他

84.26%

股东类型

持股股东

占比

Investment Advisor

18.38%

Investment Advisor/Hedge Fund

4.70%

Hedge Fund

3.22%

Research Firm

2.98%

Individual Investor

1.70%

Pension Fund

0.36%

Bank and Trust

0.03%

其他

68.64%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

304

9.95M

37.38%

2025Q3

332

9.95M

41.39%

+217.92K

2025Q2

334

9.73M

47.54%

+407.61K

2025Q1

334

9.33M

45.75%

-2.82M

2024Q4

341

8.45M

52.98%

-249.79K

2024Q3

351

8.70M

54.68%

-447.45K

2024Q2

347

9.21M

64.12%

-1.91M

2024Q1

356

10.69M

65.28%

-2.98M

2023Q4

374

11.90M

61.88%

+645.94K

2023Q3

382

11.27M

62.51%

+267.62K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

2.53M

7.95%

-16.81K

-0.66%

Jun 30, 2025

Invus Public Equities Advisors, LLC

1.06M

3.34%

+564.25K

+112.85%

Jun 30, 2025

B. Riley Financial, Inc

756.96K

2.38%

+756.96K

Dec 31, 2024

Morgan Stanley & Co. LLC

719.75K

2.26%

+350.35K

+94.84%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

489.68K

1.54%

-1.12M

-69.54%

Jun 30, 2025

BofA Global Research (US)

420.68K

1.32%

+220.33K

+109.97%

Jun 30, 2025

Armen (Garo H.)

338.69K

1.06%

+7.51K

+2.27%

Sep 19, 2025

Millennium Management LLC

504.51K

1.58%

+504.51K

Jun 30, 2025

Geode Capital Management, L.L.C.

317.41K

-226.73K

-41.67%

Jun 30, 2025

Walleye Capital LLC

198.29K

0.62%

+198.29K

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.02%

iShares Russell 2000 Growth ETF

iShares Russell 3000 ETF

Invesco NASDAQ Future Gen 200 ETF

Fidelity Enhanced Small Cap ETF

iShares Core S&P Total U.S. Stock Market ETF

Schwab U.S. Small-Cap ETF

SPDR Portfolio MSCI Global Stock Market ETF

Global X Russell 2000 ETF

Virtus LifeSci Biotech Clinical Trials ETF

iShares Micro-Cap ETF

占比0.02%

iShares Russell 2000 Growth ETF

占比0%

iShares Russell 3000 ETF

占比0%

Invesco NASDAQ Future Gen 200 ETF

占比0%

Fidelity Enhanced Small Cap ETF

占比0%

iShares Core S&P Total U.S. Stock Market ETF

占比0%

Schwab U.S. Small-Cap ETF

占比0%

SPDR Portfolio MSCI Global Stock Market ETF

占比0%

Global X Russell 2000 ETF

占比0%

Virtus LifeSci Biotech Clinical Trials ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

公告日期

类型

比率

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

常见问题

Agenus Inc的前五大股东是谁？



Agenus Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：2.53M，占总股份比例：7.95%。
Invus Public Equities Advisors, LLC持有股份：1.06M，占总股份比例：3.34%。
B. Riley Financial, Inc持有股份：756.96K，占总股份比例：2.38%。
Morgan Stanley & Co. LLC持有股份：719.75K，占总股份比例：2.26%。
BlackRock Institutional Trust Company, N.A.持有股份：489.68K，占总股份比例：1.54%。